Antioxidant activity and spectroscopic investigations on the mechanism of interaction of methimazol-copper(II) bioactive species with bovine serum albumin

E.G. FERRER, N.M. URQUIZA, S.G. MANCA, L. LEZAMA, T. ROJO, L.G. NASO, P.A.M. WILLIAMS

Tucson, Arizona

Simposio; BioMetals 2010; 2010

Several copper complexes have been shown to possess anticancer, anticarcinogenic, and antimutagenic effects both in vitro and in vivo. In particular, in tumoral cells, the SOD activity is lower than in normal cells and as a consequence a variety of copper complexes presenting SOD-like activity were examined for anticancer antitumoral treatments. Drastic lowering of the SOD activity in erythrocytes has also been reported during methimazole administration in patients with Grave´s disease. Considering the potential SOD mimetic activity of many copper(II) complexes, and that methimazole in combination with anticancer prodrug cyclophosphamide demonstrated antitumoral effects, the antioxidant properties of bioactive methimazole-copper(II) complex have been tested. Methimazole do not show SOD activity copper complexes eshibited strong superoxide radical scavenging activity.Serum albumin is the major transport protein, and the overall distribution, metabolism, efficacy of many drugs in the body are correlated with their affinities towards this protein .For this reason, we have also investigated the mechanism of binding of our bioactive compound with BSA protein by EPR,UV-vis, Raman and Fluorescence spectroscopies.